학술논문

The path of least resistance: aggressive or moderate treatment?
Document Type
article
Source
Proceedings of the Royal Society B. 281(1794)
Subject
Emerging Infectious Diseases
Antimicrobial Resistance
6.1 Pharmaceuticals
Evaluation of treatments and therapeutic interventions
Infection
Good Health and Well Being
Anti-Infective Agents
Biological Evolution
Drug Resistance
Microbial
Humans
Infections
Microbiota
drug resistance
evolution
treatment strategies
Biological Sciences
Agricultural and Veterinary Sciences
Medical and Health Sciences
Language
Abstract
The evolution of resistance to antimicrobial chemotherapy is a major and growing cause of human mortality and morbidity. Comparatively little attention has been paid to how different patient treatment strategies shape the evolution of resistance. In particular, it is not clear whether treating individual patients aggressively with high drug dosages and long treatment durations, or moderately with low dosages and short durations can better prevent the evolution and spread of drug resistance. Here, we summarize the very limited available empirical evidence across different pathogens and provide a conceptual framework describing the information required to effectively manage drug pressure to minimize resistance evolution.